Premium
The leukemic and mononucleosis cell: III DNA synthesis
Author(s) -
Schumacher H. R.,
McFeely A. E.,
Maugel T. K.
Publication year - 1969
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196910)24:4<692::aid-cncr2820240406>3.0.co;2-z
Subject(s) - mononucleosis , thymidine , dna synthesis , leukemia , formate , acute leukemia , medicine , precursor cell , immunology , virology , biology , cell , dna , biochemistry , virus , catalysis
Peripheral leukocytes from 22 patients with acute leukemia, 10 patients with infectious mononucleosis, and 10 normal controls were studied by means of autoradiography and liquid scintillation techniques using C 14 formate and H 3 thymidine. Infectious mononucleosis cells showed a predictable decline with both techniques with both isotopes over a definite time period. Acute leukemic cells showed more erratic results, but in general both techniques showed a decline of utilization of both isotopes immediately after treatment and a rise in the relapse and terminal stages. This erratic nature of leukemic cells was further demonstrated by 2 cases that were studied throughout the entire duration of the disease. The results showed that the acute leukemic blast cells from all cases revealed no marked increase in endogenous synthesis (carbon 14 formate incorporation) to account for resistance, but that individual cases may release cells with variable synthetic capability over a prolonged time period. Even though cells demonstrating a variable synthetic capacity were observed, the C 14 formate‐H 3 thymidine ratio remained constant in all stages. In the terminal stage, low incorporation of both isotopes into peripheral leukemic leukocytes was rare. In contrast, mononucleosis cells showed a greater ability to utilize C 14 formate more efficiently than H 3 thymidine, and, in the later stages of the disease, incorporation of these isotopes was similar to normal controls.